Cardiotoxicity of the Anticancer Therapeutic Agent Bortezomib
- 30 June 2010
- journal article
- Published by Elsevier BV in The American Journal of Pathology
- Vol. 176 (6), 2658-2668
- https://doi.org/10.2353/ajpath.2010.090690
Abstract
Recent case reports provided alarming signals that treatment with bortezomib might be associated with cardiac events. In all reported cases, patients experiencing cardiac problems were previously or concomitantly treated with other chemotherapeutics including cardiotoxic anthracyclines. Therefore, it is difficult to distinguish which components of the therapeutic regimens contribute to cardiotoxicity. Here, we addressed the influence of bortezomib on cardiac function in rats that were not treated with other drugs. Rats were treated with bortezomib at a dose of 0.2 mg/kg thrice weekly. Echocardiography, histopathology, and electron microscopy were used to evaluate cardiac function and structural changes. Respiration of the rat heart mitochondria was measured polarographically. Cell culture experiments were used to determine the influence of bortezomib on cardiomyocyte survival, contractility, Ca(2+) fluxes, induction of endoplasmic reticulum stress, and autophagy. Our findings indicate that bortezomib treatment leads to left ventricular contractile dysfunction manifested by a significant drop in left ventricle ejection fraction. Dramatic ultrastructural abnormalities of cardiomyocytes, especially within mitochondria, were accompanied by decreased ATP synthesis and decreased cardiomyocyte contractility. Monitoring of cardiac function in bortezomib-treated patients should be implemented to evaluate how frequently cardiotoxicity develops especially in patients with pre-existing cardiac conditions, as well as when using additional cardiotoxic drugs.Keywords
Funding Information
- Fundacja na rzecz Nauki Polskiej
- American Cancer Society (IRG-84–002-22)
- Warszawski Uniwersytet Medyczny (1M19/WB1/07, 1M19/N)
- Ministerstwo Nauki i Szkolnictwa Wyższego (N301 092 32/3407, N40112331/2736, N401 3240 33)
This publication has 42 references indexed in Scilit:
- Proteasome Inhibitor PS-341 Induces Apoptosis through Induction of Endoplasmic Reticulum Stress-Reactive Oxygen Species in Head and Neck Squamous Cell Carcinoma CellsMolecular and Cellular Biology, 2004
- Prolonged Endoplasmic Reticulum Stress in Hypertrophic and Failing Heart After Aortic ConstrictionCirculation, 2004
- Voltage dependent activation of tonic contraction in cardiac myocytes.2003
- Progression From Compensated Hypertrophy to Failure in the Pressure-Overloaded Human HeartCirculation, 2003
- A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.2002
- A proteasome inhibitor confers cardioprotection.Cardiovascular Research, 2002
- Oxidative Modification and Inactivation of the Proteasome during Coronary Occlusion/ReperfusionJournal of Biological Chemistry, 2001
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processingThe EMBO Journal, 2000
- Ultrastructural Changes in Hypertrophied Myocardium of Spontaneously Hypertensive RatsJapanese Circulation Journal, 1976